Trials / Completed
CompletedNCT06757751
Antidiabetic Potential of Galician High-phenolic Extra Virgin Olive Oils in Patients With Type 2 Diabetes Mellitus.
Antidiabetic Potential of Galician High-phenolic Extra Virgin Olive Oils in Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 116 (actual)
- Sponsor
- Fundacin Biomedica Galicia Sur · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Since Galician virgin olive oils have a high content of bioactive phenolic compounds and these are attributed to a large part of the healthy properties of the Mediterranean Diet, our starting hypothesis is that these olive oils could attenuate insulin resistance, improving glycemic control in terms of fasting plasma glucose and/or glycated hemoglobin and insulin sensitivity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | EVOO diet supplement | For 24 weeks, subjects in intervention arm will have their diet supplemented, daily, with an amount of 30 ml of EVOO (Extra Virgin Olive Oil). |
Timeline
- Start date
- 2021-04-30
- Primary completion
- 2022-07-22
- Completion
- 2022-09-30
- First posted
- 2025-01-03
- Last updated
- 2025-01-06
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT06757751. Inclusion in this directory is not an endorsement.